Skip to main content

Table 3 Selected ongoing immunotherapy trials in treatment-naïve, advanced or early NSCLC

From: The next generation of immunotherapy: keeping lung cancer in check

Ongoing trial name

Phase

Histology

Therapy

Setting

Endpoints (starting with primary)

Ref

KEYNOTE-021

1/2

ALL

PEMBRO + PT-DC

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[17]

KEYNOTE-189

3

ALL

PT-DC alone versus PT-DC + PEMBRO

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[24]

IMPower 130

3

ALL

PT-DC + ATEZO

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[26]

IMPower 111

3

SQ

Gemcitabine/PT + ATEZO

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[29]

IMPower 110

3

NONSQ

Pemetrexed/PT + ATEZO

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[28]

IMPower 131

3

SQ

Abraxane/PT + ATEZO

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[27]

IMPower 150

3

NONSQ

PT-DC/ATEZO

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[25]

NEPTUNE

3

ALL

PT-DC alone versus durvalumab + tremelimumab

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[30]

MYSTIC

3

ALL

Durvalumab + tremelimumab

Advanced, treatment-naïve NSCLC

PFS, ORR, OS, DOR, safety

[31]

PEARLS

1b/2-3a

ALL

PEMBRO versus placebo

Adjuvant NSCLC

DFS, OS, lung cancer specific survival

[32]

SAKK 16/14

2

ALL

Durvalumab

Adjuvant NSCLC

Event-free survival at 1 and 5 years, OS, ORR, safety

[33]

NCT02259621

2

ALL

NIVO

Neoadjuvant NSCLC

Safety

[34]

Lung-MAP

2/3

SQ

Biomarker-driven combination with durvalumab, nivolumab, ipilimumab, and chemotherapy or targeted therapy

Advanced, pretreated SQ NSCLC

PFS, ORR, OS, DOR, safety

[16]